---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095408"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:05:33.854594+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Erasca Q2 net loss $63.2M; cash $460M; in-licenses RAS drugs, begins Phase 3

## Summary
- Net loss $63.2M ($0.29/share) vs $31.8M ($0.21/share) YOY; R&D $33M including $22.5M in-license payments.
- Cash, equivalents & securities $460.2M (up from $322M Dec 2023); runway into H1 2027.
- In-licensed pan-RAS glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001; IND filings H1 2025 and Q1 2025.
- Initiated SEACRAFT-2 Phase 3 trial for naporafenib + trametinib in NRASm melanoma; randomized data 2025.
- Phase 1b combo data in RAS Q61X tumors expected Q4 2024; initial monotherapy data for ERAS-0015/4001 in 2026.

## SEC filing metadata
- accession: 0000950170-24-095408
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017024095408/0000950170-24-095408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017024095408/eras-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095408
- JSON: https://secwatch.observer/filing/0000950170-24-095408.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.